Back to Journals » Cancer Management and Research » Volume 11

YAP/TAZ: a promising target for squamous cell carcinoma treatment

Authors Dong X, Meng L, Liu P, Ji R, Su X, Xin Y, Jiang X

Received 12 December 2018

Accepted for publication 4 June 2019

Published 8 July 2019 Volume 2019:11 Pages 6245—6252


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun

Xiaoming Dong,1,2 Lingbin Meng,3 Pinyi Liu,2 Rui Ji,4 Xuling Su,2 Ying Xin,2 Xin Jiang1

1Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, People’s Republic of China; 2Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, People’s Republic of China; 3Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA; 4Department of Biology, Valencia College, Orlando, FL 32804, USA

Abstract: Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are two homologous transcriptional coactivators and the final effectors of the Hippo signaling transduction pathway. The transcriptional activity of YAP/TAZ is dependent on their recruitment to the nucleus, which promotes binding to the transcription factor of TEA domain family members 1–4 (TEAD1-4). In Hippo-signaling pathway, YAP/TAZ is inactivated and its translocation to the nucleus is blocked via a core kinase cascade stimulated by a variety of upstream signals, such as G-protein-coupled receptor signaling, mechanical pressure, and adherens junction signaling. This pathway plays a very important role in regulating organ size, tissue homeostasis, and tumor development. In recent years, many studies have reported upregulation or nuclear localization of YAP/TAZ in a number of human malignancies, such as breast cancer, melanoma, lung cancer, especially squamous cell carcinoma in different organs. A large number of experiments demonstrate that YAP/TAZ activation promotes cancer formation, progression, and metastasis. Therefore, in this review, we summarize the evidence of regulation and function of YAP/TAZ and discuss its role in squamous cell carcinoma. Collectively, this summary strongly suggests that targeting aberrant YAP/TAZ activation is a promising strategy for the suppression of squamous cell carcinoma.

Keywords: Hippo pathway, YAP/TAZ, squamous cell carcinoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]